z-logo
Premium
Cytotoxicity and Structural Analyses of 2,2′‐Bipyridine‐, 4,4′‐Dimethyl‐2,2′‐bipyr­idine‐ and 2‐(2′‐Pyridyl)quinoxalineplatinum(II) Complexes
Author(s) -
Pages Benjamin J.,
Zhang Yingjie,
Li Feng,
Sakoff Jennette,
Gilbert Jayne,
AldrichWright Janice R.
Publication year - 2015
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.201500754
Subject(s) - chemistry , cytotoxicity , cisplatin , quinoxaline , bipyridine , stereochemistry , carboplatin , oxaliplatin , stacking , 2,2' bipyridine , medicinal chemistry , crystallography , crystal structure , in vitro , colorectal cancer , biochemistry , organic chemistry , surgery , chemotherapy , cancer , medicine
Platinum anticancer complexes incorporating 2,2′‐bipyridine (bpy), 4,4′‐dimethyl‐2,2′‐bipyridine (44Me 2 bpy) or 2‐(2′‐pyridyl)quinoxaline (2pq) as polyaromatic ligands and the S , S or R , R isomer of 1,2‐diaminocyclohexane as ancillary ligands in the form [Pt(P L )(A L )] 2+ have been synthesised and characterised. X‐ray diffraction was used to elucidate the structure and stacking behaviour of the complexes, revealing interesting properties that may impact their biological activity. Pulsed gradient spin‐echo NMR experiments elucidated the aggregation behaviour of these complexes in solution. The cytotoxicity of each complex was assessed against the L1210 murine leukaemia, HT29 human colon carcinoma and U87 human glioblastoma cell lines and compared to other complexes within this class. The complexes incorporating 44Me 2 bpy were found to be the most potent at inhibiting cell growth with IC 50 values for the S , S isomer (0.13–0.5 μ M ) less than that for cisplatin (0.36–11 μ M ), oxaliplatin (0.9–1.8 μ M ) or carboplatin (>50 μ M ). Most complexes were found to be very effective against HT29 colon carcinoma cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here